These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 19241485)
21. Laparoscopic staging and radiofrequency of hepatocellular carcinoma in liver ci rrhosis. A "bridge" treatment to liver transplantation. Casaccia M; Andorno E; Nardi I; Santori G; Troilo B; Barabino G; Di Domenico S; Panaro F; Valente U Hepatogastroenterology; 2009; 56(91-92):793-7. PubMed ID: 19621704 [TBL] [Abstract][Full Text] [Related]
22. Predicting survival in early hepatocellular carcinoma. Ryder S Gut; 2005 Mar; 54(3):328-9. PubMed ID: 15710977 [No Abstract] [Full Text] [Related]
23. Should the selection of children with hepatocellular carcinoma be based on Milan criteria? Otte JB Pediatr Transplant; 2008 Feb; 12(1):1-3. PubMed ID: 18086239 [No Abstract] [Full Text] [Related]
24. Is the search for a single comprehensive staging system for hepatocellular carcinoma an elusive one? McClune AC; Tong MJ J Clin Gastroenterol; 2009 Sep; 43(8):697-8. PubMed ID: 19636257 [No Abstract] [Full Text] [Related]
25. Selection of HCC patients for liver transplantation: the Milan criteria, Hangzhou criteria and beyond. Fan ST Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):233-4. PubMed ID: 18522876 [No Abstract] [Full Text] [Related]
26. Selection criteria for patients with hepatocellular carcinoma in liver transplantation. Kaido T; Takada Y; Uemoto S Transplantation; 2009 Aug; 88(3):442-3; author reply 443. PubMed ID: 19667951 [No Abstract] [Full Text] [Related]
27. More options and improved outcomes for hepatocellular carcinoma. Scoggins CR J Surg Oncol; 2008 Aug; 98(2):74. PubMed ID: 18623036 [No Abstract] [Full Text] [Related]
28. Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging? Yao FY; Fidelman N Hepatology; 2016 Mar; 63(3):1014-25. PubMed ID: 26560491 [TBL] [Abstract][Full Text] [Related]
36. Re: Design and endpoints of clinical trials in hepatocellular carcinoma. Di Maio M; Daniele B; Gallo C; Perrone F J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679 [No Abstract] [Full Text] [Related]
37. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Weber M; Kadry Z; Clavien PA Transplantation; 2002 Dec; 74(12):1664-5. PubMed ID: 12499876 [No Abstract] [Full Text] [Related]
38. Staging for hepatocellular carcinoma: look for a perfect classification system. Huo TI; Lee SD; Wu JC J Hepatol; 2004 Jun; 40(6):1041-2; author reply 1042-3. PubMed ID: 15158351 [No Abstract] [Full Text] [Related]
39. Many staging systems for hepatocellular carcinoma: evolution from Child-Pugh, Okuda to SLiDe. Dohmen K J Gastroenterol Hepatol; 2004 Nov; 19(11):1227-32. PubMed ID: 15482527 [No Abstract] [Full Text] [Related]
40. Critical evaluation of the different staging systems for hepatocellular carcinoma (Br J Surg 2004; 91: 400-408). Vauthey JN; Pawlik TM; Lauwers GY; Nagorney DM; Roh MS; Curley SA; Poon RT; Belghiti J; Greene F; Michael Henderson J Br J Surg; 2004 Aug; 91(8):1072. PubMed ID: 15286973 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]